에 대한 최신 뉴스 Solventum (NYSE:SOLV) 주식

Solventum

Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.

News

Hedge Funds

Politics

GEHC

Janus Henderson Group plc Ordinary Shares

SOLV

넬슨 펠츠가 이끄는 헤지펀드 트라이언 펀드 매니지먼트(Trian Fund Management)는 3분기 13F 공시에서 2024년 미국 대통령 선거를 앞두고 주요 기업에 대해 대규모 투자 엑시트 단행했던 포트폴리오 변화를 공개했다.

넬슨 펠츠가 이끄는 트라이언 펀드 매니지먼트의 美 대선 전 포트폴리오 재구성

Personal Finance

ARKK

HUMA

INTC

PARA

PARAA

SSBK

미국 의회 의원들의 주식 거래 활동은 위원회 임무를 포함한 이해 상충이 거래에 영향을 미칠 수 있다는 가능성으로 인해 투자자들로부터 지속적으로 관심을 끌고 있다. 잘 알려진 한 의회 의원은 금요일 시장 마감 무렵에 여러 거래를 공개했다.

미 상원 의원 토미 튜버빌은 여러 대형주의 매도와 매수 포지션 공개

Solventum Corp

SOLVE

SOLVAC SA by SOLVAC SA

SOLVBL SOLUTIONS INC by SOLVBL SOLUTIONS INC.

SoLVBL Solutions Inc

SOLVAY BANK SOLVAY NY by Solvay Bank (NY)

Solvay Bank

Solvay SA

Management

Dana Appoints Current Director R. Bruce McDonald As Chairman And CEO

Universal Health Realty Income Trust (NYSE:&nbsp;UHT) announced today that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.735 per share on December 31, 2024 to shareholders of record as of December 16, 2024.

Dividends

Universal Health Realty Income Trust Announces Dividend Increase From $0.73 To $0.735 Per Share

Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
In the previous quarter, the company beat on EPS by $0.4, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BLBD

Blue Bird Earnings Review: Q4 Summary

Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Earnings Report: Q4 Overview

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.38 in the previous quarter, leading to a 1.0% increase share price change the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Enanta Pharma: Q4 Earnings Insights

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.11, leading to a 6.0% increase share price change the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENT

Insights into Central Garden & Pet Q4 Earnings

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Pennant Park Investment missed estimated earnings by 0.0%, reporting an EPS of $0.22 versus an estimate of $0.22.
Revenue was up $2.46 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.
Here's a look at Pennant Park Investment's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.24</td>
<td>0.22</td>
<td>0.24</td>
<td>0.24</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>36.66M</td>
<td>36.34M</td>
<td>32.74M</td>
<td>34.83M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>37.00M</td>
<td>35.98M</td>
<td>34.34M</td>
<td>34.04M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Pennant Park Investment <a href="https://www.benzinga.com/quote/PNNT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNNT

Recap: Pennant Park Investment Q4 Earnings

The earnings results for PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) for Q4 were made public on Monday, November 25, 2024 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
PennantPark Floating Rate missed estimated earnings by 0.0%, reporting an EPS of $0.32 versus an estimate of $0.32.
Revenue was up $19.79 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company missed on EPS by $0.01, leading to a 0.0% increase share price change the next day.
Here's a look at PennantPark Floating Rate's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.31</td>
<td>0.31</td>
<td>0.33</td>
<td>0.32</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>45.52M</td>
<td>39.45M</td>
<td>35.01M</td>
<td>34.59M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>48.51M</td>
<td>44.35M</td>
<td>37.97M</td>
<td>35.73M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for PennantPark Floating Rate <a href="https://www.benzinga.com/quote/PFLT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PFLT

PennantPark Floating Rate Earnings Review: Q4 Summary

The earnings results for StealthGas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GASS#NASDAQ">GASS</a>) for Q3 were made public on Monday, November 25, 2024 at 09:10 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
StealthGas beat estimated earnings by 15.0%, reporting an EPS of $0.38 versus an estimate of $0.33.
Revenue was up $5.79 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.22 in the last quarter, resulting in a 2.0% drop share price change the following day.
Here's a look at StealthGas's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.24</td>
<td>0.30</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.75</td>
<td>0.53</td>
<td>0.29</td>
<td>0.16</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>39.20M</td>
<td>34.30M</td>
<td>33.90M</td>
<td>27.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>41.79M</td>
<td>41.56M</td>
<td>34.14M</td>
<td>34.65M</td>
</tr>
</tbody>
</table>

To track all earnings releases for StealthGas <a href="https://www.benzinga.com/quote/GASS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GASS

StealthGas Q3 Earnings Assessment

Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:26 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Fluence Energy beat estimated earnings by 13.0%, reporting an EPS of $0.34 versus an estimate of $0.3.
Revenue was up $555.02 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.11 in the last quarter, resulting in a 15.0% increase share price change the following day.
Here's a look at Fluence Energy's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.07</td>
<td>-0.13</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>-0.07</td>
<td>-0.14</td>
<td>0.02</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>455.51M</td>
<td>578.76M</td>
<td>407.61M</td>
<td>515.67M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>328.09M</td>
<td>623.14M</td>
<td>363.96M</td>
<td>672.98M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Fluence Energy <a href="https://www.benzinga.com/quote/FLNC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLNC

Fluence Energy Earnings Review: Q4 Summary

Asset Sales

Spruce Power Holding Corporation Class A Common Stock

SPRU

NJR Clean Energy Ventures Announces The Sale Of Its Residential Solar Portfolio To Spruce Power Holding For $132.5M

Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. This is a 1600 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $1.23 billion which missed the analyst consensus estimate of $1.30 billion by 5.61 percent. This is a 82.47 percent increase over sales of $672.98 million the same period last year.

Earnings Beats

Earnings Misses

Fluence Energy Q4 2024 GAAP EPS $0.34 Beats $0.31 Estimate, Sales $1.23B Miss $1.30B Estimate

WIIM

SANW

S&W Seed shares are trading higher after the company announced it has finalized the voluntary plan of administration  process for its subsidiary, S&W Seed Company Australia.

BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.03 by 233.33 percent. The company reported quarterly sales of $784.20 million which beat the analyst consensus estimate of $776.51 million by 0.99 percent.

TBBB

BBB Foods Q3 EPS $0.10 Beats $0.03 Estimate, Sales $784.20M Beat $776.51M Estimate

As previously reported, S&amp;W Australia adopted a voluntary administration process on July 24, 2024, and on October 11, 2024 creditors of S&amp;W Australia approved a proposed Deed of Company Arrangement pursuant to which, among other things, 100% of the shares in S&amp;W Australia would be transferred to Avior Asset Management No. 3 Pty Ltd. The effective date of the DOCA is November 22, 2024.&nbsp;

S&W Seed Finalizes Voluntary Plan Of Administration Process For Subsidiary S&W Australia; On November 22, S&W Entered Settlement Agreement In Exchange For Release From Intercompany Obligations Owed To S&W Australia

SMTC

Semtech shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales, and provided Q4 EPS and revenue guidance above analyst estimates.

Semtech shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance with its midpoint above estimates.

Astronics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) ("Astronics" or the "Company") today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2030 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Astronics also expects to grant to the initial purchasers of the Notes an option to purchase up to an additional $15 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued.

Offerings

ATRO

Astronics Corporation Announces $150M Convertible Senior Notes Due 2030 Offering

LESL

Leslie's shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS and sales.

The Q4 earnings report for Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) was released on Monday, November 25, 2024 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Leslies missed estimated earnings by -82.0%, reporting an EPS of $0.02 versus an estimate of $0.11.
Revenue was down $34.51 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
In the previous quarter, the company missed on EPS by $0.08, resulting in a 14.000000000000002% increase change in the share price the following day.
Here's a look at Leslies's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.42</td>
<td>-0.18</td>
<td>-0.21</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.34</td>
<td>-0.17</td>
<td>-0.20</td>
<td>0.14</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>615.41M</td>
<td>200.92M</td>
<td>169.61M</td>
<td>419.39M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>569.64M</td>
<td>188.66M</td>
<td>173.96M</td>
<td>432.37M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Leslies <a href="https://www.benzinga.com/quote/LESL/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Leslies Earnings Report: Q4 Overview

FY24 consensus $6.38. Raises FY24 Organic sales growth to the upper half of 0% to +1.0% (previously 0% to +1.0%); Free cash flow of $750M to $850M ...

Solventum raises FY24 adjusted EPS view to $6.50-$6.65 from $6.30-$6.50

Solventum Corporation ( ($SOLV) ) has released its Q3 earnings. Here is a breakdown of the information Solventum Corporation presented to its inves...

Solventum Raises Guidance Amid Modest Sales Growth

In a report released yesterday, Travis Steed from Bank of America Securities reiterated a Hold rating on Solventum Corporation (SOLV – Research Rep...

Travis Steed Maintains Hold Rating on Solventum Corporation Amid Uncertainties and Potential Volatility

Solventum Corporation 2024 Q3 - Results - Earnings Call Presentation

Solventum Corporation (SOLV) Q3 2024 Earnings Call Transcript

Assessing MedTech impact from potential China tariffs

Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of September 30, 2024. Trian's one new buy during the third quarter...

Trian exits Disney stake, takes new position in Ferguson

Trian exits Disney, Rentokil among Q3 moves, almost entirely sheds GE HealthCare

Tracking Seth Klarman's Baupost Group Holdings - Q3 2024 Update

Morgan Stanley lists hedge funds' largest Q3 ownership increases in Russell 1000 stocks

ACHC

AZEK

BILL

BRBR

CAVA

CHRW

CIVI

CLVT

CPRI

CTLT

FERG

FTRE

GDHLF

GOOG

GOOGL

JAZZ

LBTYA

LBTYB

LBTYK

LITE

MASI

MTCH

NVST

QGEN

RKLIF

SNRE

TBPH

TNDM

UHAL

VRSN

VSAT

WING

Press Releases

Solventum Reports Second Quarter 2024 Financial Results and Raises Full-Year Guidance

Solventum autonomous coding listed in Epic Toolbox

Solventum to Participate in Upcoming Investor Conferences

Solventum Launches All-In-One, Extended-Wear Wound Dressing for V.A.C.® Therapy

Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

Commodities

Solventum Announces Commitment to 100% Renewable Electricity by 2030

Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance

Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment

Solventum to Participate in the Piper Sandler Healthcare Conference

Align Tech

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

WORK Medical Technology Group LTD - Ordinary Shares

WORK Medical Technology

Dentsply Sirona

Morgan Stanley

Piper Sandler

Stifel

Goldman Sachs

Wells Fargo

넬슨 펠츠가 이끄는 헤지펀드 트라이언 펀드 매니지먼트(Trian Fund Management)는 3분기 13F 공시에서 <a href="//www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy"" target="_blank" rel="noopener">2024년 미국 대통령 선거</a>를 앞두고 주요 기업에 대해 대규모 투자 엑시트 단행했던 포트폴리오 변화를 공개했다.
무슨 일이 있었나:  트라이언 펀드 매니지먼트는 GE 헬스케어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>)(134만 주), 월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)(265만 주), 그리고 렌토킬 이니셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>)(47만 주)에 대한 전체 지분을 매각했다.
이러한 매각은 시장 도전과 거시경제적 압박에 직면한 헬스케어 및 엔터테인먼트와 같은 부문에서 신중한 방향 전환을 시사한다.
또한 트라이언펀드는 몇몇 핵심 보유 종목의 지분을 줄였다. 웬디스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>)에서의 보유 지분을 3% 줄여 3,150만 주에서 3,050만 주로, 그리고 자산운용사 인베스코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>)에 대한 투자도 15% 줄여 2,720만 주에서 2,310만 주로 축소했다.
가장 큰 감소는 트라이언펀드가 보유 주식을 69% 감소시켜 613,447주로 줄인 올스테이트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>)에서 발생했다. 이러한 감소는 최근 시장 변동성과 경제 불확실성의 영향을 받은 섹터에 대한 전략적 긴축을 반영한다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%98%EB%A6%AC%EC%97%87%EC%9D%B4-3%EB%B6%84%EA%B8%B0%EC%97%90-%EC%9B%A8%EC%8A%A4%ED%84%B4-%EB%94%94%EC%A7%80%ED%84%B8-%EC%97%A3%EC%8B%9C%EB%8A%94-%EC%B6%94%EA%B0%80-%EC%94%A8%EB%93%9C%EB%A6%B4/" target="_blank" rel="noopener">엘리엇이 3분기에 웨스턴 디지털, 엣시는 추가; 씨드릴, 블랙라인, NRG 에너지는 축소</a>
기타 사항: 하지만 일부 기업에서는 포지션을 강화했다. 솔벤트럼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>)의 지분을 536만 주에서 713만 주로 늘렸고, 재너스 헨더슨 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)과 제너럴 일렉트릭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>)에서는 보유 지분을 유지했다.
이러한 포지션 증가는 잠재적인 산업 및 금융 부문 성장의 혜택을 받을 수 있는 부문에 대한 트라이언펀드의 자신감과 같은 맥락이다.
트라이언펀드가 3분기에 포트폴리오를 변경한 직후, 2024년 미국 대통령 선거에서 도널드 트럼프의 승리와 함께 상원 공화당 과반수 확보가 확정되었다. 앞으로 법인세 인하, 관세 인상, 친환경 에너지 이니셔티브의 잠재적 후퇴 등 트럼프의 정책 의제는 시장에 큰 영향을 미칠 것으로 예상된다.
전통적인 제조업, 방위, 에너지와 같은 부문은 트럼프 행정부 하에서 특히 산업 및 금융 투자에서 트라이언의 포트폴리오 변화에 따라 이익을 볼 수 있다.
트라이언의 최근 움직임은 트럼프의 백악관 복귀로 인해 변화하는 경제 환경에 대비하는 헤지펀드의 미래지향적 전략을 잘 나타낸다.
이미지 출처: Midjourney를 통해 AI로 생성
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 의회 의원들의 주식 거래 활동은 위원회 임무를 포함한 이해 상충이 <a href="https://www.benzinga.com/topic/congress-trading" target="_blank" rel="noopener" data-google-interstitial="false">거래에 영향</a>을 미칠 수 있다는 가능성으로 인해 투자자들로부터 지속적으로 관심을 끌고 있다.
잘 알려진 한 의회 의원은 금요일 시장 마감 무렵에 여러 거래를 공개했다.
무슨 일이 있었나 (What Happened): 의회 거래 활동에 대한 관심이 높아짐에 따라 여러 의회 거래 ETF가 생성되었으며 새로운 <a href="https://www.benzinga.com/etfs/specialty-etfs/24/06/39299113/nancy-pelosi-among-best-of-the-best-in-stock-trading-new-congress-trading-etf-coming-from-cre">ETF</a>도 곧 만들어지고 있다.
상원 의원 토미 튜버빌(공화-알라바마주)은 의회에서 가장 활동적인 거래자 중 한 명이며 과거 거래에 대한 조사를 받았다. 이 상원 의원의 거래는 종종 대량과 큰 금액으로 이루어진다.
금요일에 튜버빌은 주로 이전 포지션의 매도와 신규 및 기존 포지션에 대한 콜옵션 및 풋옵션 매수로 이루어진 대량의 거래를 <a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noopener" data-google-interstitial="false">공개</a>했다.
대규모 거래로는 클리블랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) 주식 매각, 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) 주식 매각, 휴마사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) 포지션 청산 등이 포함됐다.
튜버빌은 또한 Ark Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)의 콜과 풋을 매입했다.
이 상원의원은 또한 합병 가능성이 결렬된 미디어 회사인 파라마운트 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/paraa" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for PARAA">PARAA</a>)의 주식도 매각했다.
최근 공개된 옵션 이외의 유일한 매수는 인텔 주식 추가와 헬스케어 기업인 솔벤텀 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>)의 1,000~15,000달러 포지션이었다.
&#8220;속보: 튜버빌 상원의원은 언론 보도를 피하기 위해 의도적으로 금요일 오후에 수백만 달러의 거래를 보고했다&#8221;라고 콩그레스트레이딩(Congresstrading)이 금요일 <a href="https://x.com/congresstrading/status/1801709082299994303" target="_blank" rel="noopener">트윗</a>했다.
관련 링크: <a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin">독점: 주식투자로 이익 챙긴 2명의 의회 의원 비판…&#8217;팬데믹 기간 국민들 고생할 때 돈 벌이&#8217;</a>
왜 중요한가 (Why It&#8217;s Important): 튜버빌은 의회의 <a href="https://www.benzinga.com/government/24/04/38304279/tommy-tuberville-trades-raise-eyebrows-again-senator-sells-put-options-buys-small-biotech-linked-to" target="_blank" rel="noopener" data-google-interstitial="false">여러 위원회</a>에 소속돼 있다. 이로 인해 군사위원회에 배치되면서 휴마사이트와 같은 그의 주식 거래에 대한 관심이 높아지고, 상원 농업, 영양 및 임업 위원회에 배치되면서 운송 및 상품 관련 주식에 대한 관심이 높아졌다.
휴마사이트는 이전에도 러시아-우크라이나 전쟁 중 우크라이나에서 사용되는 제품과 연결되어 거래자들로부터 주목을 받았다.
올해 초 튜버빌이 지역 은행인 서던 스테이츠 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>)의 주식을 50,000~100,000달러 매입했다는 공개가 이 은행의 CEO가 이전에 튜버빌의 캠페인에 기부했다는 사실이 알려지면서 <a href="https://www.benzinga.com/general/politics/24/03/37829749/senator-tommy-tubervilles-latest-2-stock-trades-attract-the-wrong-kind-of-attention-should-this-" target="_blank" rel="noopener" data-google-interstitial="false">관심을 끌었다</a>.
튜버빌은 또한 조 바이든 대통령이 CHIPS 법에 서명하기 전에 인텔 주식을 구매한 바 있다. 이 CHIPS 법은 인텔을 포함한 칩 회사들에 500억 달러의 자금을 지원했다.
튜버빌의 담당자는 이전에 몽고메리 애드버타이저(Montgomery Advertiser)에게 자신의 포트폴리오를 관리하는 재정 자문가가 있다고 <a href="https://www.montgomeryadvertiser.com/story/news/politics/2022/09/13/senator-tommy-tuberville-stock-conflicts-committee-alabama-new-york-times/69491542007/" target="_blank" rel="noreferrer noopener">말했다</a>.
일부 의회 의원들은 주식 및 옵션 거래 금지를 지지했지만, 튜버빌은 과거에도 이러한 조치를 "말도 안 되는 일"이라며 반대해왔다.
"여기에 와서 봉사하려는 사람들의 수가 정말 줄어들 것이라고 생각한다. 정말 그렇다. 그런 것이 필요하지 않다"라고 튜버빌이 2022년에 더 <a href="https://www.benzinga.com/general/politics/24/04/38304279/tommy-tuberville-trades-raise-eyebrows-again-senator-sells-put-options-buys-small-biotech-linked-to">인디펜던트</a>(The Independent)에 말했다.
사진: 셔터스톡을 통한 튜버빌 상원의원의 사진

Comments

Solventum

뉴스

에 대한 최신 뉴스 Solventum (NYSE:SOLV) 주식

금요일, 11월 15, 2024

월요일, 6월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌